Form 10-Q · Quarterly report
Kimberly-Clark 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0000055785
- Accession no.
- 0001628280-26-052348
Summary
Kimberly-Clark reported second-quarter 2026 net sales of $4.189 billion, up 0.6%, and net income attributable to the company of $345 million, down 32.2%, while adjusted earnings per share from continuing operations rose 10.4% to $1.80. The quarter included $109 million of charges related to the Kenvue Acquisition and a $60 million loss from discontinued operations, net of income taxes.
Key points
- Second-quarter net sales were $4,189 million, up 0.6% from a year earlier; six-month net sales were $8,352 million, up 1.6%.
- Second-quarter net income attributable to Kimberly-Clark was $345 million, down 32.2%; six-month net income was $1,010 million, down 6.1%.
- Second-quarter adjusted earnings per share from continuing operations were $1.80, up 10.4%, and adjusted operating profit was $757 million, up 6.2%.
- The company reported $109 million of Kenvue Acquisition-related charges in the quarter and $72 million of pre-tax separation costs in discontinued operations.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Results of Operations Consolidated Results Summary of Results Three Months Ended June 30 Six Months Ended June 30 2026 2025 % Change 2026 2025 % Change Net Sales $ 4,189 $ 4,163 0.6 % $ 8,352 $ 8,217 1.6 % Gross Profit 1,603 1,456 10.1 % 3,137 2,965 5.8 % Operating Profit 633 592 6.9 % 1,386 1,223 13.3 % Provision for income taxes (217) (116) 87.1 % (381) (247) 54.3 % Income from Continuing Operations 410 444 (7.7) % 984 914 7.7 % Income (Loss) from Discontinued Operations, Net of Income Taxes (60) 68 (188.2) % 41 171 (76.0) % Net Income Attributable to Kimberly-Clark Corporation 345 509 (32.2) % 1,010 1,076 (6.1) % Diluted Earnings per Share from Continuing…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.